AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10383531 — intervention group
Group type: COMPARATOR
Intervention: Pancreatin microspheres
Number of subjects: 37
Study 10383531 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatin minimicrospheres and microspheres
Number of subjects: 37
Study 8922305 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal diacylglycerol (DAG) concentrations
Number of subjects: 12
Study 8922305 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake
Number of subjects: 12
Study 8922305 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of calories from dietary fat
Number of subjects: 12
Study 8922305 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber and calcium intake
Number of subjects: 12
Study 8922305 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal DAG
Number of subjects: 12
Study 1670740 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 15
Study 1670740 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 15
Study 1670740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30470568 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60mg/day + usual analgesic regimens
Number of subjects: 46
Study 30470568 — intervention group
Group type: COMPARATOR
Intervention: Usual analgesic regimens (morphine±acetaminophen±gabapentin)
Number of subjects: 46
Study 28917062 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 89
Study 28917062 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% with adrenaline
Number of subjects: 89
Study 28917062 — intervention group
Group type: COMPARATOR
Intervention: No infiltration (Control)
Number of subjects: 89
Study 26366481 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT4) treatment
Number of subjects: 136
Study 26366481 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 136
Study 23410544 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful strict rate control (resting heart rate <80 beats/min, during moderate exercise <110 beats/min)
Number of subjects: 614
Study 23410544 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed strict rate control
Number of subjects: 614
Study 23410544 — intervention group
Group type: COMPARATOR
Intervention: Lenient rate control (resting heart rate <110 beats/min)
Number of subjects: 614
Study 22123031 — intervention group
Group type: EXPERIMENTAL
Intervention: mobiletype program (intervention group)
Number of subjects: 114
Study 22123031 — intervention group
Group type: COMPARATOR
Intervention: attention comparison group (control group)
Number of subjects: 114
Study 22123031 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 114
Study 20796302 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTi‐SP
Number of subjects: 522
Study 20796302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 522
Study 17439866 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement and brief behavioral intervention
Number of subjects: 383
Study 15088993 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic fatigue syndrome patients (disabled from working)
Number of subjects: 1000
Study 12138652 — intervention group
Group type: EXPERIMENTAL
Intervention: F-18 fluorodeoxyglucose positron emission tomography (FDG-PET)
Number of subjects: 0
Study 12138652 — intervention group
Group type: COMPARATOR
Intervention: Conventional morphological imaging methods (ultrasonography, radiography, CT, MRI)
Number of subjects: 0
Study 9926055 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive sector clients
Number of subjects: 0
Study 9926055 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive sector
Number of subjects: 0
Study 9926055 — intervention group
Group type: COMPARATOR
Intervention: Both sectors
Number of subjects: 0
Study 7651645 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative autologous blood collection with autotransfusion (Cell Saver)
Number of subjects: 71
Study 7651645 — intervention group
Group type: COMPARATOR
Intervention: Historic controls (not using Cell Saver)
Number of subjects: 71
Study 2699653 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg metoclopramide
Number of subjects: 50
Study 2699653 — intervention group
Group type: COMPARATOR
Intervention: 2 mg/kg metoclopramide
Number of subjects: 50
Study 2699653 — intervention group
Group type: EXPERIMENTAL
Intervention: High dosage of cisplatin (70-100 mg/m2) or ethylenediamine platinum II malonate (800-900 mg/m2)
Number of subjects: 50
Study 2699653 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of metoclopramide
Number of subjects: 50
Study 2699653 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum metoclopramide levels
Number of subjects: 50
Study 989393 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 989393 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserine
Number of subjects: 0
Study 989393 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior-oriented evaluation scale
Number of subjects: 0
Study 989393 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-verbal behavior assessment
Number of subjects: 0
Study 31216748 — intervention group
Group type: EXPERIMENTAL
Intervention: Action removal method
Number of subjects: 0
Study 31216748 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaustive approach
Number of subjects: 0
Study 31216748 — intervention group
Group type: EXPERIMENTAL
Intervention: Shrink-Reduce approach
Number of subjects: 0
Study 31216748 — intervention group
Group type: COMPARATOR
Intervention: State-of-the-art approach
Number of subjects: 0
Study 27902522 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical use of Petroselinum crispum (parsley)
Number of subjects: 0
Study 27902522 — intervention group
Group type: COMPARATOR
Intervention: Hydroquinone cream
Number of subjects: 0
Study 26425941 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet
Number of subjects: 254
Study 26425941 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet plus text message
Number of subjects: 254
Study 26425941 — intervention group
Group type: COMPARATOR
Intervention: Usual waitlist control
Number of subjects: 254
Study 26425941 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 254
Study 23469148 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 IU oxytocin
Number of subjects: 120
Study 23469148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 21377002 — intervention group
Group type: EXPERIMENTAL
Intervention: NTtrap stone occlusion device
Number of subjects: 113
Study 21377002 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard procedure)
Number of subjects: 113
Study 21377002 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 113
Study 18990368 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdose flare-up protocol (n = 45)
Number of subjects: 90
Study 18990368 — intervention group
Group type: COMPARATOR
Intervention: Antagonist multiple-dose protocol (n = 45)
Number of subjects: 90
Study 17175305 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcineurin inhibitor-free (CNI) protocol
Number of subjects: 3
Study 17175305 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy (tacrolimus, prednisone, mycophenolate mofetil)
Number of subjects: 3
Study 17175305 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone-free protocol
Number of subjects: 3
Study 12634513 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine and Olanzapine
Number of subjects: 29
Study 16464205 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical interventions; compliance with economic evaluation guidance
Number of subjects: 301
Study 16464205 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling approach for pharmaceuticals; compliance with economic evaluation guidance
Number of subjects: 301
Study 16464205 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trials (RCTs) or modeling data; economic evaluations
Number of subjects: 301
Study 9360688 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver ring mounted on peritoneal dialysis catheter
Number of subjects: 174
Study 9360688 — intervention group
Group type: COMPARATOR
Intervention: Control group (no silver ring)
Number of subjects: 174
Study 8256318 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion with whole blood (n = 56)
Number of subjects: 197
Study 8256318 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion with blood free from leucocytes (n = 48)
Number of subjects: 197
Study 8256318 — intervention group
Group type: COMPARATOR
Intervention: No blood transfusion (n = 93)
Number of subjects: 197
Study 2439815 — intervention group
Group type: EXPERIMENTAL
Intervention: Bopindolol 2 mg
Number of subjects: 12
Study 2439815 — intervention group
Group type: EXPERIMENTAL
Intervention: Bopindolol 4 mg
Number of subjects: 12
Study 2439815 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 30 mg
Number of subjects: 12
Study 2439815 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 12
Study 2439815 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 12
Study 2439815 — intervention group
Group type: EXPERIMENTAL
Intervention: Bopindolol 8 mg
Number of subjects: 12
Study 29862619 — intervention group
Group type: EXPERIMENTAL
Intervention: ipragliflozin 50 mg/day
Number of subjects: 143
Study 29862619 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 143
Study 27269306 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg/kg with 50% oxygen inhalation (group H)
Number of subjects: 21
Study 27269306 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.05 mg/kg with normal air inhalation (group N)
Number of subjects: 21
Study 25224360 — intervention group
Group type: EXPERIMENTAL
Intervention: eBST ≥ 11.4 ng/ml
Number of subjects: 900
Study 25224360 — intervention group
Group type: COMPARATOR
Intervention: Normal BST
Number of subjects: 900
Study 22571978 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma insulin levels in men with nonamnestic or amnestic MCI
Number of subjects: 549
Study 22571978 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma insulin levels in women with amnestic MCI
Number of subjects: 549
Study 22571978 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE ε4 genotype influence on insulin levels
Number of subjects: 549
Study 19727797 — intervention group
Group type: EXPERIMENTAL
Intervention: L(-)-menthol (0.01%)
Number of subjects: 9
Study 19727797 — intervention group
Group type: COMPARATOR
Intervention: Orange-flavoured placebo solution
Number of subjects: 9
Study 18922850 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric articaine 84 mg
Number of subjects: 97
Study 18922850 — intervention group
Group type: COMPARATOR
Intervention: Plain articaine 84 mg
Number of subjects: 97
Study 16268751 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized intervention (printed advisory sent to clinicians at each patient visit)
Number of subjects: 4500
Study 16268751 — intervention group
Group type: COMPARATOR
Intervention: General guideline implementation (education about guideline‐based drug recommendations)
Number of subjects: 4500
Study 12160198 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril
Number of subjects: 37
Study 12160198 — intervention group
Group type: EXPERIMENTAL
Intervention: bendrofluazide
Number of subjects: 37
Study 12539298 — intervention group
Group type: EXPERIMENTAL
Intervention: TSPP/STPP/HCS dentifrice (1% tetrasodium polyphosphate, 7% sodium tripolyphosphate, 0.243% sodium fluoride, 10% high cleaning silica)
Number of subjects: 91
Study 12539298 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice (sodium fluoride/silica without stain removal ingredients)
Number of subjects: 91
Study 10155230 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic intraaortic balloon pump (IABP) support
Number of subjects: 40
Study 10155230 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous cardiopulmonary bypass (PCPB) support
Number of subjects: 40
Study 2354690 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose iron supplements (18-20 mg iron/d) containing haem iron and non-haem iron
Number of subjects: 45
Study 2354690 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose iron supplements (18-20 mg iron/d) containing non-haem iron only
Number of subjects: 45
Study 2354690 — intervention group
Group type: EXPERIMENTAL
Intervention: All low-dose iron supplements
Number of subjects: 45
Study 2354690 — intervention group
Group type: COMPARATOR
Intervention: None of the supplements
Number of subjects: 45
Study 6781157 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment with beta-receptor blocker propranolol, alone or in combination with dihydralazine and/or hydrochlorothiazide for 8 years.
Number of subjects: 135
Study 6781157 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with unsatisfactory results.
Number of subjects: 135
Study 31754961 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 36
Study 31754961 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue-Retaining Device (TRD)
Number of subjects: 36
Study 31464577 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradiscal platelet-rich plasma (PRP) injections
Number of subjects: 0
Study 31464577 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30253790 — intervention group
Group type: COMPARATOR
Intervention: Universal prevention (Climate)
Number of subjects: 2190
Study 30253790 — intervention group
Group type: COMPARATOR
Intervention: Combined universal and selective prevention (CAP)
Number of subjects: 2190
Study 30253790 — intervention group
Group type: EXPERIMENTAL
Intervention: Control (Health education as usual)
Number of subjects: 2190
Study 26955895 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based eating and stress management practices
Number of subjects: 194
Study 24365774 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased LV compliance (measured as reduced LV end‐diastolic volume at an idealized LV end‐diastolic pressure of 20 mm Hg)
Number of subjects: 419
Study 24365774 — intervention group
Group type: EXPERIMENTAL
Intervention: RV remodeling (indicated by increased RV wall thickness)
Number of subjects: 419
Study 24365774 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite endpoint of cardiovascular hospitalization or death
Number of subjects: 419
Study 24365774 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization for heart failure (HF)
Number of subjects: 419
Study 23069099 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography integrated with advanced cardiac life support (ACLS) protocol (Group A)
Number of subjects: 100
Study 23069099 — intervention group
Group type: COMPARATOR
Intervention: Conventional ACLS protocol without echocardiography (Group B)
Number of subjects: 100
Study 20108344 — intervention group
Group type: EXPERIMENTAL
Intervention: etaracizumab alone
Number of subjects: 112
Study 20108344 — intervention group
Group type: EXPERIMENTAL
Intervention: etaracizumab + dacarbazine
Number of subjects: 112
Study 17334144 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical negative pressure
Number of subjects: 0
Study 15728930 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at 80 ppm for 72 hours
Number of subjects: 0
Study 15728930 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy for pulmonary tuberculosis
Number of subjects: 0
Study 11849632 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive patch (Ortho Evra/Evra)
Number of subjects: 3330
Study 11849632 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive (Triphasil)
Number of subjects: 3330
Study 10516746 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction treatment (698 patients)
Number of subjects: 784
Study 10516746 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction treatment in patients >/=60 years
Number of subjects: 784
Study 10516746 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction treatment in patients <60 years
Number of subjects: 784
Study 10516746 — intervention group
Group type: EXPERIMENTAL
Intervention: Period of diagnosis (1980-84/85-89/90-95)
Number of subjects: 784
Study 10516746 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional combined chemotherapy in patients >/=60 years
Number of subjects: 784
Study 10516746 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival rates
Number of subjects: 784
Study 10516746 — intervention group
Group type: EXPERIMENTAL
Intervention: No significant change in DFS and CR durations
Number of subjects: 784
Study 8592718 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) referral
Number of subjects: 2147
Study 8592718 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy implementation within 1 month of back injury
Number of subjects: 2147
Study 8592718 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender and specific diagnosis
Number of subjects: 2147
Study 8592718 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of physical therapy
Number of subjects: 2147
Study 2013419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily with NSAID treatment
Number of subjects: 190
Study 2013419 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily without NSAID treatment
Number of subjects: 190
Study 7036300 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance BCG therapy
Number of subjects: 93
Study 7036300 — intervention group
Group type: COMPARATOR
Intervention: No other treatment (Control)
Number of subjects: 93
Study 30716200 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line chemotherapy (2L CT)
Number of subjects: 144
Study 28598730 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed message
Number of subjects: 552
Study 28598730 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed message
Number of subjects: 552
Study 28598730 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced-framed message
Number of subjects: 552
Study 27085870 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (12.5 mg at 2300) and Nabilone (3 mg at 0900 and 1800)
Number of subjects: 11
Study 27085870 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (12.5 mg at 2300)
Number of subjects: 11
Study 27085870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 23815763 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-control intervention
Number of subjects: 30
Study 22453547 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% CO(2) inhalation
Number of subjects: 23
Study 22453547 — intervention group
Group type: COMPARATOR
Intervention: Normal/medical air (control)
Number of subjects: 23
Study 19814838 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk supplementation (2 years)
Number of subjects: 757
Study 19814838 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein intake (55.9‐61.0 g/d on average)
Number of subjects: 757
Study 19814838 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein from animal foods (particularly meat)
Number of subjects: 757
Study 17645791 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU follow-up programme with clinic appointments at 2-3 and 9 months after ICU discharge
Number of subjects: 270
Study 17645791 — intervention group
Group type: COMPARATOR
Intervention: Standard in-hospital follow-up
Number of subjects: 270
Study 16176401 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 196
Study 16176401 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 196
Study 12032194 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux haemodialysis
Number of subjects: 74
Study 10409598 — intervention group
Group type: EXPERIMENTAL
Intervention: High-hormone phase (progesterone/estrogen)
Number of subjects: 8
Study 10409598 — intervention group
Group type: COMPARATOR
Intervention: Low-hormone phase (placebo)
Number of subjects: 8
Study 7672489 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin therapy
Number of subjects: 31
Study 7672489 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous fast‐acting insulin
Number of subjects: 31
Study 2205907 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 86
Study 2205907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 7043728 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 1 g daily
Number of subjects: 0
Study 7043728 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 750 mg daily
Number of subjects: 0
Study 31955711 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA algorithms based on Krylov subspace and randomized singular value decomposition
Number of subjects: 0
Study 31955711 — intervention group
Group type: COMPARATOR
Intervention: Existing fast and memory-efficient PCA algorithms
Number of subjects: 0
Study 30471973 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mouthwash
Number of subjects: 0
Study 30471973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29096671 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive focal drug administration (RFDA) using dihydroartemisinin‐piperaquine (DHAP)
Number of subjects: 4800
Study 29096671 — intervention group
Group type: COMPARATOR
Intervention: Reactive focal test and treat (RFTAT) using artemether‐lumefantrine (AL)
Number of subjects: 4800
Study 26065506 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chloramphenicol eye ointment
Number of subjects: 60
Study 26065506 — intervention group
Group type: COMPARATOR
Intervention: 2.5% povidone-iodine ophthalmic solution
Number of subjects: 60
Study 23521128 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 777
Study 23521128 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐CdA (cladribine)
Number of subjects: 777
Study 23521128 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 777
Study 23521128 — intervention group
Group type: EXPERIMENTAL
Intervention: IT therapy responses
Number of subjects: 777
Study 20646083 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 mg of Wheat Extract Oil (WEO)
Number of subjects: 51